TNFRSF9 and ovarian carcinoma: Antibodies which activate the T-cell co-stimulatory receptor CD137 or block the co-inhibitory receptor PD-1 have demonstrated broad anti-tumor effects but have not improved the survival of mice with poorly immunogenic tumors, including the ID8 murine ovarian cancer, when used as single agents [25,39,40].